• 1
    Cannon PJ, Stason WB, Demartini FE, et al.Hyperuricemia in primary and renal hypertension. N Engl J Med. 1966;275:457464.
  • 2
    Nagahama K, Inoue T, Iseki K, et al.Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res. 2004;27:835841.
  • 3
    Verdecchia P, Schillaci G, Reboldi G, et al.Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension. 2000;36:10721078.
  • 4
    Kanbay M, Ozkara A, Selcoki Y, et al.Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39:12271233.
  • 5
    Kanbay M, Huddam B, Azak A, et al.A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol. 2011;6:18871894.
  • 6
    Khan F, George J, Wong K, et al.Allopurinol treatment reduces arterial wave reflection in stroke survivors. Cardiovasc Ther. 2008;26:247252.
  • 7
    George J, Carr E, Davies J, et al.High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114:25082516.
  • 8
    Alderman MH. Podagra, uric acid, and cardiovascular disease. Circulation. 2007;116:880883.
  • 9
    Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300:924932.
  • 10
    Jadad AR, Moore RA, Carroll D, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials. 1996;17:112.
  • 11
    Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med. 2001;135:982989.
  • 12
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177188.
  • 13
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:15391558.
  • 14
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629634.
  • 15
    Goicoechea M, de Vinuesa SG, Verdalles U, et al.Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:13881393.
  • 16
    Momeni A, Shahidi S, Seirafian S, et al.Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iran J Kidney Dis. 2010;4:128132.
  • 17
    Noman A, Ang DS, Ogston S, et al.Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375:21612167.
  • 18
    Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:5159.
  • 19
    Dogan A, Yarlioglues M, Kaya MG, et al.Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Press. 2011;20:182187.
  • 20
    Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:18111821.
  • 21
    Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131:713.
  • 22
    Kobrin I, Frohlich ED, Ventura HO, Messerli FH. Renal involvement follows cardiac enlargement in essential hypertension. Arch Intern Med. 1986;146:272276.
  • 23
    Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58:87114.
  • 24
    Santos CX, Anjos EI, Augusto O. Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation. Arch Biochem Biophys. 1999;372:285294.
  • 25
    Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840844.
  • 26
    Khosla UM, Zharikov S, Finch JL, et al.Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67:17391742.
  • 27
    Wallace SM, Yasmin , McEniery CM, et al.Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction. Hypertension. 2007;50:228233.
  • 28
    Victor VM, Rocha M, Sola E, et al.Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des. 2009;15:29883002.
  • 29
    Corry DB, Eslami P, Yamamoto K, et al.Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26:269275.
  • 30
    McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis. 1981;40:245249.